Table 1.
Characteristics of the real-world studies enrolled in qualitative synthesis and meta-analysis.
| Author | N Patients |
Age Median (Range) |
Male % |
Smoker % |
Histology % |
Stage % |
PS % |
Prior RT % |
Metastases % |
Cycles ICIs % |
Line % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adachi et al., 2020 [19] | 296 n | 70 (IQR: 64–76) |
70 | 80 | ADC: 62 Sq: 27 Other: 10 |
nr | 0: 14 1: 61 2: 18 3: 5 4: 2 |
21 | Brain: 26 Liver: 14 |
nr | 2: 49 3: 23 4: 13 >4: 15 |
| Chen et al., 2020 [20] | 97 62 n 35 p |
64 (IQR: 57–69) ≥65: 49 |
67 | 59 | Non sq: 60 Sq: 40 |
III: 23 IV: 77 |
0–1: 84 ≥2: 15 |
28 | nr | nr | 2: 74 ≥3: 26 |
| Dupont et al., 2020 [21] | 191 n | 63 (IQR: 56–68) |
63 | 90 | ADC:71 Sq: 23 Other: 6 |
III: 9 IV: 91 |
0: 19 1: 69 2: 8 3: 3 4: 0.5 |
nr | Brain: 23 | nr | 2: 48 3: 38 >3: 14 |
| Figueiredo et al., 2020 [22] | 219 n | 64 (37–83) ≥75:15 |
70 | 69 | Non sq: 88 Sq: 12 |
IIIB: 8 IV: 92 |
0: 12 1: 75 2: 13 |
nr | Brain: 0 | 14 (1–52) |
2: 32 3: 38 ≥4: 29 |
| Joris et al., 2020 [23] | 324 n | 65 (28–86) ≥70: 33 ≥75: 14 |
65 | 85 | Non sq: 66 Sq: 28 Other: 6 |
nr | 0–1: 69 ≥2: 27 Nos: 4 |
nr | nr | nr | 2: 52 3: 28 >3: 20 |
| Martin et al., 2020 [24] | 109 n | Mean 65 (56–72) |
58 | 75 | Non sq: 78 Sq: 20 Nos: 2 |
IV:100 | 0–1: 83 2–3: 16 Nos: 2 |
61 | nr | 10 (IQR: 3–18) |
Median before: 2 (1–4) |
| Pantano et al., 2020 [25] | 294 n | 67 (34–90) | 68 | 86 | ADC: 54 Sq: 42 Other:4 |
I-II: 11 * III: 23 IV: 65 |
0: 52 1: 44 2: 4 |
36 | Brain: 14 Liver: 12 |
nr | 2: 65 3: 23 >3: 12 |
| Russo et al., 2020 [26] | 187 n | 67 (34–83) |
73 | 90 | Non sq: 54 Sq: 46 |
IIIB or IV | 0: 45 1: 51 2: 4 |
nr | nr | nr | Median 2 (2–8) |
| Velcheti et al., 2020 [27] | 349 p | 68 (37–84) ≥75:25 |
57 | 92 | Non sq: 58 Sq: 37 NSCLC nos: 4 |
IIIB-IV: 86 | 0: 26 1: 49 2: 18 3: 7 |
nr | Brain: 9 | nr | 2: 92 3: 7 ≥4: 1 |
| Kim et al., 2020 [28] | 83 n | 60 (IQR: 53–68) |
66 | 63 | Non sq: 70 Sq: 30 |
IV:100 | 0–1: 76 ≥2: 24 |
nr | CNS: 34 | nr | 2: 43 ≥3: 57 |
| Zhang et al., 2020 [29] | 73 n | nr | 75 | nr | ADC: 57 Non sq: 37 Other: 5 |
III: 4 IV: 96 |
0–1: 90 ≥2: 10 |
nr | Brain: 44 | nr | 2: 82 ≥3: 19 |
| Baldini et al., 2020 [30] | 1959 n | 66 (27–91) |
68 | 73 | Non sq: 81 Sq: 19 |
nr | 0: 40 1: 52 2: 7 |
nr | Brain: 23 Liver: 20 |
7 (1–55) |
2: 40 3: 29 ≥4: 30 |
| Crinò et al., 2019 [31] | 371 n | 68 (31–91) ≥75: 19 |
80 |
83 | Sq: 100 | ≥IIIB | 0: 36 1: 58 2: 6 |
nr | CNS: 10 Liver: 17 |
Mean: 6 (1–22) | 2: 44 3: 32 ≥4: 24 |
| Fukui et al., 2019 [32] | 52 n | 69 (46–83) ≥75:21 |
71 | 82 | ADC: 63 Sq: 31 Nos: 6 |
III: 25 IV:75 |
0: 37 1: 58 2: 4 3: 2 |
nr | Brain 15 Liver: 19 |
4 (1–43) |
2: 42 3: 29 ≥4: 29 |
| Grossi et al., 2019 [33] | 1588 n | 66 (27–89) |
65 | 71 | Non sq: 100 | IIIb or IV | 0: 41 1: 51 2: 7 |
nr | CNS: 26 Liver: 21 |
7 (1–55) |
2: 24 3: 35 ≥4: 40 |
| Lang et al., 2019 [34] | 70 37 n 26 p 7 a |
mean 66 (39–85) |
60 | 80 | ADC: 79 Sq: 30 |
III: 4 IV: 96 |
0: 24 1: 63 2: 13 |
nr | CNS: 23 | nr | 2: 100 |
| Merino Almazan et al., 2019 [35] | 221 n | Mean 64 >70: 27 |
84 | 69 | Non sq: 38 Sq: 60 |
I-II: 8 * III: 38 IV: 54 |
0:28 1: 57 2: 14 |
9 | Brain: 10 Liver: 19 |
Mean 9.7 (1–48) |
2: 65 3: 28 ≥4: 7 |
| Muchnik et al., 2019 [36] | 75 65 n 6 p 4 other |
Mean 74 (70–92) |
52 | nr | ADC: 68 Other: 32 |
IIIB: 3 IV: 97 |
0: 4 1: 47 2: 45 3: 4 |
nr | nr | nr | 2: 16 3: 69 ≥4: 15 |
| Weis et al., 2019 [37] | 81 n | 64 | 48 | 85 | Non sq:60 Sq: 32 Other: 7 |
IV: 100 | 0: 17 1: 54 ≥2: 28 |
nr | nr | 3 (1–18) |
2: 64 ≥3: 36 |
| A 43 | 67 | 53 | 81 | Non sq: 67 Sq: 28 Other: 5 |
IV:100 | 0: 16 1: 63 ≥: 21 |
nr | nr | 4 (1–36) |
2: 74 ≥3: 26 |
|
| Schwartzberg et al., 2019 [38] | 2071 1842 n 186 p 38 a |
Mean 68 ≥75: 27 |
56 | 92 | Non sq: 64 Sq: 31 Nos: 5 |
I-IIIA: 16 * IIIB-IV: 83 Nos: 2 |
0: 21 1: 50 2: 24 ≥3: 5 |
nr | nr | nr | 2: 91 3: 9 |
| El Karak et al., 2019 [39] | 110 55 n 55 p |
66 | 75 | 88 | ADC: 57 Sq: 30 Nos: 13 |
IV: 100 | Nr | nr | Brain: 17 Liver: 15 |
nr | 2: 68 3: 24 ≥4: 8 |
| Spigel et al., 2019 [40] | 1426 n | 67 (23–93) ≥70: 9 |
54 | 87 | Non sq: 71 Sq: 28 Nos: 1 |
IIIB: 8 IV: 91 |
0: 23 1: 66 2: 9 |
nr | nr | nr | 2: 39 3: 28 ≥4: 32 |
| Areses Manrique et al., 2018 [41] | 188 n | 58 (45–81) ≥70: 7 |
77 | 91 | ADC: 60 Sq: 35 Nos: 5 |
IIIB: 31 IV: 67 |
0: 8 1: 82 2: 10 |
nr | CNS: 22 | 6 (1–34) |
2: 62 3: 24 ≥4: 14 |
| Garde-Noguera et al., 2018 [42] | 175 n | 61.5 ≥70: 26.8 |
73 | 91 | Non sq: 77 Sq: 23 |
III: 13 IV: 87 |
0–1: 81 2: 19 |
17 | Brain: 22 Liver: 23 |
2: 37 3: 38 ≥4: 25 |
|
| Fujimoto et al., 2018 [43] | 613 n | Mean 66.9 | 71 | 79 | ADC: 67 Sq: 22 Other: 10 |
IIIB: 6 IV: 94 |
0–1: 77 2: 15 3–4: 8 |
nr | nr | nr | 2: 33 3: 25 ≥4: 42 |
| Juergens et al., 2018 [44] | 472 n | 66 (36–92) >75: 13 |
43 | 54 | Non sq: 73 Sq: 26 Other: 1 |
nr | 0–1: 86 ≥2: 9 Nos: 5 |
nr | Brain: 13 | nr | 2: 44 3: 29 ≥4: 26 |
| Kobayashi et al., 2018 [45] | 142 n | 67 (34–85) ≥75: 27 |
75 | 80 | ADC: 58 Sq: 29 Other: 13 |
IIIA: 13 IIIB: 15 IV: 60 |
0: 30 1: 53 2: 11 3: 6 |
32 | CNS: 19 | nr | 2: 40 ≥3: 60 |
| Nakaya et al., 2018 [46] | 101 n | 69 (45–84) |
77 | 84 | Non sq: 63 Sq: 37 |
nr | 0–1: 84 ≥2: 16 |
nr | nr | nr | 2: 18 3: 28 ≥4: 55 |
| Tamiya et al., 2018 [47] | 201 n | 68 (27–87) |
67 | 78 | ADC: 71 Sq: 21 Other: 8 |
IV:100 | 0: 16 1: 60 2: 16 ≥3: 7 |
nr | Brain: 25 Liver: 14 |
nr | ≤3: 61 ≥4: 39 |
| Toumoy et al., 2018 [48] | 267 n | 66 (41–86) |
72 | 92 | Non sq: 73 Sq: 27 |
III: 4 IV: 96 |
0: 16 1: 60 2: 24 |
52 | Brain: 17 Liver: 21 |
6 (1–43) |
2: 52 3: 33 ≥4: 16 |
| Bagley et al., 2017 [49] | 175 n | 68 (33–88) ≥75: 25 |
46 | 84 | Non sq: 76 Sq: 24 |
nr | 0: 17 1: 58 2: 22 3: 3 |
nr | CNS: 31 Liver: 23 |
5 (1–24) |
2: 54 3: 25 ≥4: 21 |
| Brustugun et al., ** 2017 [50] | 58 n | 65 (32–88) |
48 | nr | ADC: 55 Sq: 41 Other: 3 |
I-II: 14 III: 42 IV: 62 |
0: 19 1: 57 2: 17 3: 7 |
nr | Brain: 0 | 8.5 (1–32) |
2: 34 3: 47 ≥4:18 |
| Kobayashi et al., 2017 [51] | 50 n | 65 (39–76) |
60 | 62 | Non sq: 88 Sq: 12 |
III: 20 IV: 58 rec: 22 |
0: 26 1: 64 2: 10 |
32 | nr | 4 (1–20) |
2: 20 3: 18 ≥4: 62 |
* stage at diagnosis; ** not in meta-analysis; n = nivolumab; p = pembrolizumab; a = atezolizumab; nr = not reported; rec = recurrence after surgery.